

Clinical Appointments to Medical Advisory Board and Wholesale Order of Incannex™ CBD Oils

Highlights:

- Associate Professor Michael Stubbs is an experienced and respected specialist in the treatment of patients with temporomandibular disorders, among other oral issues
- Dr David Cunnington is a specialist sleep physician who has affiliations with the Melbourne Clinic and St Vincent's Private Hospital in East Melbourne and will advise Impression on its sleep apnoea clinical program
- These appointments add clinical expertise and depth to Impression's Medical Advisory Board that is led by medicinal cannabis expert, Chief Medical Officer of Impression and CEO of Cannvalate Pty Ltd, Dr Sud Agarwal
- Impression previously announced the appointment of Dr Ron Jithoo and Dr Simon Hinckfuss on the 29th of August 2019 to guide clinical programs into TBI/Concussion and Periodontitis (Gum Disease)
- The four Medical Board advisors will assist with all facets of the clinical trials, product development, procuring funding grants, assisting with research documentation and presenting research findings at conferences/clinical meetings
- Impression has placed its first order for Incannex™ cannabidiol ('CBD') oils from Linnea SA, the Company's chosen supplier of high-grade botanical extracts and pharmaceutical ingredients of natural origin for use in the pharmaceutical industry.

Impression Healthcare Limited ('Impression', 'IHL' or the 'Company'), developer of four unique medicinal cannabis products, owner of Incannex™ cannabis oils and oral devices manufacturer, has appointed another two leading medical experts to its Medical Advisory Board, overseen by Dr Sud Agarwal.

Associate Professor Michael Stubbs and Dr David Cunnington are key opinion leaders in their respective specialties of Temporomandibular Joint Disorders ('TMD') and Sleep Apnoea. Both advisors have commenced for an initial term of two years to assist with; all facets of the TMD and Sleep Apnoea clinical trials, procuring funding grants, product development, assisting with research documentation and presenting research findings at conferences/clinical meetings.

Chief Medical Officer and non-executive director of Impression healthcare, Dr Sud Agarwal said;

"We're delighted to have formally appointed another two experienced medical professionals, with solid academic research credentials, to the medical advisory board. Associate Professor Michael Stubbs and Dr David Cunnington are globally recognised Key Opinion Leaders (KOLs) in their clinical fields."

"As real-world clinicians with specialised clinical practices highly relevant to our research needs, they will be invaluable in shaping our novel cannabinoid drug discovery programs and shaping the target properties of our novel drugs."

“Incannex™ has four cannabinoid-based New Molecular Entities (NME’s) in preclinical drug development where the over-arching strategy is to create novel, patent-protected, clinically validated, FDA/ EMA/ TGA registerable products with specific therapeutic claims.”

Associate Professor Michael Stubbs BDS MDS MDSc FRACDS

Associate Professor Michael Stubbs is an oral medicine specialist practitioner based in Melbourne, Victoria, with a special interest in Temporomandibular Disorders for the treatment of facial and jaw pain. He is an associate professor in oral medicine at Latrobe University and an editor of 'Australasian Dentist' Magazine with a multitude of research and professional education publications.

Prior to his current roles, Associate Professor Stubbs was Head of the Oral Medicine Unit at the Alfred Hospital in Melbourne between the years of 2006-2015, national vice president of the Oral Medicine Society of Australia and New Zealand and a Visiting Lecturer at the School of Dental Science, University of Melbourne 2003-2011. Associate Professor Stubbs website is here: www.michaelstubbs.com.au

Dr David Cunnington MBBS MMedSc MAppMgt FRACP FCCP RPSGT DBSM

Dr David Cunnington is a specialist sleep physician, co-director of Melbourne Sleep Disorders Centre, and co-founder of the online sleep resource, SleepHub.com.au. David is a Fellow of the Royal Australasian College of Physicians, a Diplomat of Behavioural Sleep Medicine (DBSM), Registered Polysomnographic Technologist (RPSGT) and holds a Masters degrees in Medical Science (Pharmaco-epidemiology and economics specialisation) and Applied Health Management (Quality assurance specialisation).

David is an experienced investigator with original research, editorials and reviews published in leading medical journals on a range of sleep disorders. David appears regularly in traditional and social media as a commentator on sleep, promoting positive health messages about sleep and sleep health and is an invited speaker at both national and international conferences on sleep. Dr David Cunnington’s website is here: www.drdauidcunnington.com.au

Incannex™ CBD Oils Wholesale Purchase Order from Linnea SA

Impression announced on the 08th of August that, in parallel with IHL’s clinical trials being undertaken to create proprietary IP-defendable cannabinoid products, IHL under the Incannex™ brand, had also launched a line of EU GMP-approved pharmaceutical grade CBD Oil products to treat conditions previously approved for treatment with cannabinoids under Special Access Scheme (‘Incannex™ Oils’).

IHL is pleased to report that the first batch of CBD Incannex™ Oil has been ordered from Linnea SA. The Incannex™ Oils can be sold under Australia’s largest distribution network - Cannvalate - on a non-exclusive basis. The Incannex Oils have been designed to match with the formulations most in demand on the Cannvalate network, which receives 100+ new patient enquiries per day.

ENDS

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited (IHL.ASX) is undertaking four clinical trials investigating the use of uniquely formulated medicinal cannabis products for the treatment of Obstructive Sleep Apnoea, Traumatic Brain Injury/Concussion, Periodontitis (Gum Disease) and Temporomandibular Joint Disorder. Each indication represents major global markets.

IHL has its Australian licenses in place to import, export and distribute cannabis products and has launched a line of EU GMP-approved CBD oil products under the brand, "Incannex™". Incannex™ oils may be sold under IHL's product supply and distribution agreement with Cannvalate Pty Ltd – the largest network of cannabis medicine prescribers in Australia.

Impression also has a collaboration and "first right of refusal" agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Incorporated and a license agreement with Resolution Chemicals for the production and distribution of Dronabinol in the USA, Canada, Australia and New Zealand.

Providing growing revenues to the Company; Impression continues to build its customised oral devices manufacturing business both direct-to-the-consumer and via the Company's growing B2B preferred practitioner network.

Investors: investors@impression.healthcare

Website: www.impression.healthcare

For personal use only